

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	ATTORNEY DOCKET NO. CONFIRMATION NO.	
09/762,491	05/09/2001	Ying Luo	A-68285/RMS/	4855	
20350 75	590 03/30/2004		EXAMINER		
TOWNSEND	AND TOWNSEND AN	YU, MISOOK			
TWO EMBARCADERO CENTER EIGHTH FLOOR		ART UNIT	PAPER NUMBER		
SAN FRANCISCO, CA 94111-3834			1642		
			DATE MAILED: 03/30/2004	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/762,491	LUO ET AL.				
Advisory Action	Examiner	Art Unit				
	MISOOK YU, Ph.D.	1642				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
THE REPLY FILED 25 November 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expiresmonths from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
1. A Notice of Appeal was filed on 29 December 2003. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) ☐ they raise the issue of new matter (see Note below);						
(c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) ☐ they present additional claims without canceling a corresponding number of finally rejected claims. NOTE:						
3. Applicant's reply has overcome the following rejection(s): none.						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.						
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. ☐ For purposes of Appeal, the proposed amendment(s) a) ☐ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected is Claim(s) rejected: <u>1-20 and 25</u> .						
Claim(s) rejected. <u>1-20 and 20.</u> Claim(s) withdrawn from consideration:						
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.						
a The same with the same and the same Market Paragraphs (a)						
10.⊠ Other: <u>See Continuation Sheet</u>	LARRY R. HELMS, PH.D PRIMARY EXAMINER	Misook Yu, 3/25/2005				
i '	Linia					

Continuation of 5. does NOT place the application in condition for allowance because: Claims 1, 3, 4, 6-12, 15-20, 25, and 26 remain rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for SEQ ID NO:5 encoding for the Apo3 protein (SEQ ID NO:6) and a deletion mutant for inducing apoptosis. The specification is not enabled for the full scope because the specification does not teaches which 15 % could be changed without affecting the recited function. As stated in the two previous Office actions, the specification is enabled for only two species i.e. SEQ ID NO:5 encoding SEQ ID NO:6 and one other nucleic molecule encoding a deletion mutant.

Continuation of 10. Other: The information disclosure statement filed 08/04/2003 fails to comply with 37 CFR 1.97(d) because it lacks a statement as specified in 37 CFR 1.97(e). It has been placed in the application file, but the information referred to therein has not been considered..